The Efficacy of Rivaroxaban in Reducing the Risk of Cardiovascular Events in Patients with Stable Ischemic Heart Disease and Peripheral Disease. Results of the COMPASS Trial

Nadezhda M. Savina

For citations:

Savina N.M. The Efficacy of Rivaroxaban in Reducing the Risk of Cardiovascular Events in Patients with Stable Ischemic Heart Disease and Peripheral Disease. Results of the COMPASS Trial. Kardiologiia. 2018;58(3):94-100. (In Russ.) https://doi.org/10.18087/cardio.2018.3.10103

Views PDF (Rus): 1632

This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 0022-9040 (Print)
ISSN 2412-5660 (Online)

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

User

Kardiologiia

For citations:

Cookies policy